Compare iShares Gold Trust (IAU) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs Revvity Inc — how do they compare? iShares Gold Trust trades at $78.87 (market cap $61.51B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: iShares Gold Trust is far larger — about 3.6× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while iShares Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 49 Days and Revvity Inc for 12 Days on average.
| IAU | RVTY | |
|---|---|---|
Market Cap | $61.51B | $16.98B |
Volume | 3,206,729 | 1,456,900 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $157.36 |
52-Week Low | $74.21 | $82.26 |
Typical Hold Time | 49 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU stock trades at $77.66 with a modest 0.78% daily gain amid bearish technical signals. The stock faces significant selling pressure with moving averages indicating a strong downtrend while oscillators remain neutral. Recent news highlights gold's sensitivity to interest rate expectations and Treasury yield movements, with mixed sentiment from financial media regarding near-term prospects.
The outlook remains cautious with technical indicators favoring sellers, though oversold conditions could present tactical opportunities. Key risks include persistent rate hike expectations and dollar strength, while institutional positioning suggests defensive sentiment prevails in the current macroeconomic environment.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
